The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.
Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.